Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812027 · ClinicalTrials.gov registry record
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
A clinical trial of Non-Small Cell Lung Cancer and Head and Neck Cancer, sponsored by TScan Therapeutics.
- Active
- Registry status
- 1,150
- Enrollment target
- 20
- Study locations
NCT05812027: Active study of Non-Small Cell Lung Cancer and Head and Neck Cancer, sponsored by TScan Therapeutics.
NCT05812027 is a study of Non-Small Cell Lung Cancer and Head and Neck Cancer that is active but no longer recruiting, run by TScan Therapeutics. The registered enrollment target is 1,150 participants, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (77% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05812027, a study of Non-Small Cell Lung Cancer and Head and Neck Cancer, is active but no longer recruiting, sponsored by TScan Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 1,150 participants
- Enrollment target
- 20
- Study locations
Study Summary
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.
Primary Outcome
To identify participants that could potentially be eligible for the TScan Therapeutics clinical trials.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tumor and HLA Profiling
Study Locations (20)
Florida
- Memorial Healthcare System - Hollywood
- University of Miami, Sylvester Comprehensive Cancer Center - Miami
- Orlando Health - Orlando
- University of South Florida - Tampa
Ohio
- Oncology Hematology Care - Cincinnati
- The Cleveland Clinic - Cleveland
Pennsylvania
- Allegheny Hospitals Network - Pittsburgh
- University of Pittsburgh Medical Center - Pittsburgh
Arizona
- HonorHealth Research and Innovation Institute - Scottsdale
California
- University of California San Diego - San Diego
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago - Chicago
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2027-01-14 |
What the registry record for NCT05812027 still lists
NCT05812027 is an observational study that tracks outcomes without assigning an intervention. Its 1,150 participants enrollment target places it among the larger protocols in the corpus, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (77% higher).
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tumor and HLA Profiling is the first listed.
NCT05812027 names 20 study sites across 15 states, led by Florida, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05812027 about?
NCT05812027 is a clinical study titled "A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors". TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to ...
What is the current status of trial NCT05812027?
This trial is currently active not recruiting. The enrollment target is 1,150 participants. The study started on 2023-06-26. Estimated completion is 2027-01-14.
What conditions does trial NCT05812027 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Head and Neck Cancer, Cervical Cancer, Sarcoma, Uveal Melanoma.
What interventions are being tested in trial NCT05812027?
The interventions under investigation include: Tumor and HLA Profiling (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05812027?
This trial is sponsored by TScan Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05812027 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05812027's enrollment target sits among peer trials
1,150 19th of 454 higher than 436 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
- NCT07339423 · 1,150 participants · Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI